Abstract
Brain metastases (BMs) are common among patients with lung cancer and have been associated with treatment failure and limited survival. Approximately 25% of NSCLC patients present with BMs at first diagnosis. Patients treated with 3rd generation EGFR-tyrosine kinase inhibitors (TKIs), including aumolertinib and osimertinib, showed a lower risk of progression and better responses with EGFRm NSCLC and BMs. Studies suggested EGFR-TKI plus bevacizumab had PFS benefits for patients with CNS metastases, and combination strategies of chemotherapeutic agents and TKI also demonstrated the potential to improve survival.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
